Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
739 Emerging proteomic and safety analysis of blood from solid tumor patients receiving TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2) monotherapy in TUNIMO phase 1 clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.